title: Clinical utility of radioimmunoscintigraphy of non-Hodgkin's lymphoma with radiolabelled LL2 monoclonal antibody, LymphoSCAN: preliminary results.
abstract: OBJECTIVE
  Adequate clinical staging of non-Hodgkin's lymphoma patients is essential because only localized disease can be treated satisfactorily. Many imaging procedures are necessary to stage the disease accurately. The objective of this study was to evaluate the efficacy of an antilymphoma antibody in the Fab' fragment form, labelled with 99mTc, to detect malignant lesions.
  
  
  METHODS
  Radioimmunodetection (RAID) with 99mTc-labelled B-cell lymphoma monoclonal antibody IMMU-LL2-Fab' (LymphoSCAN; Immunomedics, Morris Plain, NJ, USA) was investigated in 10 patients (5 females and 5 males; age range, 20-72 years) with histologically proved non-Hodgkin's lymphoma. Of the 10 lymphomas, 7 were intermediate grade and 3 were low grade. Whole body images with multiple planar views were obtained at 30 min, 4-6 and 24 h after i.v. injection of 1 mg LL2-Fab' labelled with 740-925 MBq of 99mTc. SPET of the chest or abdomen was performed in all patients 5-8 h after the immunoreagent injection.
  
  
  RESULTS
  No adverse reactions were observed in any patient after Mab infusion, and no appreciable changes were seen in the blood counts, renal or liver function tests. A total of 18 of 21 (85.7%) lymphoma lesions were detected by RAID. All the tumor localizations were confirmed by clinical examination and with other imaging techniques, such as CT scan, MRI or gallium scan. In this series of patients no false-positive results were noted. As regards the biodistribution of the immunoreagent, no appreciable bone marrow activity was seen; splenic targeting was demonstrated in all patients; the tumor-to-non-tumor ratios ranged from 1.2 to 2.8 ad measured by the ROI technique; no difference in uptake was noted for different tumor grades. The images obtained 24 h after injection did not reveal new lesions, but areas of doubtful uptake were seen as positive focal areas in the delayed scan.
  
  
  CONCLUSIONS
  LymphoSCAN seems to be useful for detection, staging and follow-up of non-Hodgkin's lymphoma patients.
authors.affiliation: Nuclear Medicine Department, National Cancer Institute, Milan, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Gasparini
authors.forename: E
authors.initials: E
authors.lastname: Bombardieri
authors.forename: C
authors.initials: C
authors.lastname: Tondini
authors.forename: L
authors.initials: L
authors.lastname: Maffioli
authors.forename: L
authors.initials: L
authors.lastname: Hughes
authors.forename: G L
authors.initials: GL
authors.lastname: Burraggi
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging*; D008297:Male; D008875:Middle Aged; D016719:Radioimmunodetection / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; C095913:bectumomab